Antineoplastic Temozolomide CAS 85622-93-1 Raw Materials Powder

CAS: 85622-93-1

MF: C6H6N6O2

Specification​: 99% min Temozolomide Powder

Sample: Temozolomide Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

MADE IN CHINA Store:https://henrikang.en.made-in-china.com/

Temozolomide Powder Usage and Synthesis :

Temozolomide Powder is the first orally effective imidazolotetrazine antitumor drug.Temozolomide Raw Materials belongs to the second generation of alkylating agents with antitumor activity.Temozolomide CAS 85622-93-1 is an antibiotic and belongs to the aminoglycoside class of drugs. It can inhibit protein synthesis of bacteria, thus acting as a bactericide.

Temozolomide is mainly used for the treatment of infections caused by sensitive bacteria, such as respiratory tract infections, urinary tract infections, skin and soft tissue infections, osteomyelitis, and sepsis. Temozolomide is administered intravenously, and the dose and duration of treatment depend on the patient's condition.
However, it should be noted that Temozolomide may cause side effects such as nephrotoxicity and hearing impairment and should be used under medical supervision.

Application/Function of Temozolomide Powder.

Temozolomide is the first orally effective imidazolotetrazine antitumor drug and is a second-generation alkylating agent with antitumor activity, which does not require intrahepatic metabolic activation after oral administration. It is also a first-line drug for the treatment of metastatic melanoma.

Translated with www.DeepL.com/Translator (free version)

Temozolomide rapidly breaks down to produce active methyl diazo ions. Since brain tumors are more basic than surrounding tissues, the activation of this drug can be relatively concentrated at the tumor site, with strong and selective anti-tumor effects, improved side effect profile, less bone marrow toxicity, and improved patient tolerance.

Production method of Temozolomide Powder .

Temozolomide was synthesized by Cancer Research UK and later transferred to Schering-Plough in the United States for development. Unlike existing antitumor drugs, it has a novel chemical structure and is an imidazolotetrazine derivative. Temozolomide does not act directly, but is rapidly converted to the active compound MTIC [5-(3-methyltriazen-1-yl)imidazol-4-amide] via a non-enzymatic pathway at physiological pH.

The cytotoxicity of MTIC is thought to arise mainly from its DNA alkylation (methylation), which occurs mainly at the O6 and N7 positions of guanine. Temozolomide has been shown to be effective in some of the most common glioblastomas in basic and clinical studies, and was approved for marketing in the European Union and the United States in 1999, with the approved indications in the United States being second-line treatment of glioblastomas such as pleomorphic glioblastoma and degenerative astrocytoma, and the approved indications in countries belonging to the European Union being pleomorphic glioblastoma with progression or recurrence of disease despite conventional treatment.

The role of temozolomide in glioblastoma multiforme has gained more recognition in Europe.

The effects of temozolomide in the treatment of recurrent glioblastoma multiforme have been confirmed to be safe and effective in clinical trials. The results of a phase II randomized controlled trial showed that 225 patients with first recurrence of glioblastoma multiforme were treated with temozolomide or procarbazine (every 56 days for 28 d at 125-150 mg/m2 orally daily), respectively, for 6 months, with no progression in the temozolomide group.

The survival rate and overall survival rate were 21% and 60%, respectively, which were significantly higher than 8% and 44% in the procarbazine group. The mean progression-free survival and overall survival time for temozolomide patients were 2.9 and 7.3 months, respectively, also significantly higher than the 1.9 and 5.8 months in the procarbazine group. The trial also evaluated health-related quality of life at months 3 and 6 after treatment initiation, which also confirmed that more patients in the temozolomide group had improved or maintained stable quality of life.

Antineoplastic agents. The active metabolite MTIC is spontaneously and rapidly degraded in vivo to produce antitumor effects. Used as an antitumor agent.